Wordt geladen...
Sequential allogeneic and autologous CAR-T–cell therapy to treat an immune-compromised leukemic patient
CAR-T–cell therapy normally requires the patient’s own healthy T cells. An allogeneic CAR-T bridging therapy could rescue lymphopenic patients.
Bewaard in:
| Gepubliceerd in: | Blood Adv |
|---|---|
| Hoofdauteurs: | , , , , , , , |
| Formaat: | Artigo |
| Taal: | Inglês |
| Gepubliceerd in: |
American Society of Hematology
2018
|
| Onderwerpen: | |
| Online toegang: | https://ncbi.nlm.nih.gov/pmc/articles/PMC6058233/ https://ncbi.nlm.nih.gov/pubmed/30026294 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1182/bloodadvances.2018017004 |
| Tags: |
Voeg label toe
Geen labels, Wees de eerste die dit record labelt!
|